Compare AOSL & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOSL | SPTX |
|---|---|---|
| Founded | 2000 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.6M | 929.8M |
| IPO Year | 2007 | 2026 |
| Metric | AOSL | SPTX |
|---|---|---|
| Price | $23.44 | $16.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $42.75 | $37.00 |
| AVG Volume (30 Days) | ★ 479.7K | 275.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,291,000.00 | N/A |
| Revenue This Year | $2.83 | N/A |
| Revenue Next Year | $11.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.01 | $15.79 |
| 52 Week High | $54.34 | $28.38 |
| Indicator | AOSL | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.48 | 35.45 |
| Support Level | $20.38 | N/A |
| Resistance Level | $26.25 | $22.75 |
| Average True Range (ATR) | 1.16 | 1.49 |
| MACD | -0.37 | -0.22 |
| Stochastic Oscillator | 2.24 | 14.27 |
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and Other countries. The company is operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.